Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1

Metastatic colorectal cancer (mCRC) patients have poor overall survival despite using irinotecan- or oxaliplatin-based chemotherapy combined with anti-EGFR (epidermal growth factor receptor) drugs, especially those with the oncogene mutation of KRAS. Metformin has been reported as a potentially nove...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Proc Natl Acad Sci U S A
Autors principals: Xie, Jinye, Xia, Liangping, Xiang, Wei, He, Wenzhuo, Yin, Haofan, Wang, Fang, Gao, Tianxiao, Qi, Weiwei, Yang, Zhonghan, Yang, Xia, Zhou, Ti, Gao, Guoquan
Format: Artigo
Idioma:Inglês
Publicat: National Academy of Sciences 2020
Matèries:
Biological Sciences
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7293710/
https://ncbi.nlm.nih.gov/pubmed/32444490
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1918845117
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars